Multiple Sclerosis Market Set to Reach USD 33.57 Billion by 2032, Growing at a CAGR of 5.4% | Polaris Market Research (PMR)
19. August 2024 08:25 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Market Overview: The multiple sclerosis market was estimated at USD 21.04 billion in 2023. The market valuation is expected to be USD 33.57 billion...
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
04. Dezember 2023 07:09 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Emerald Health Pharmaceuticals Receives Safety Review Committee Approval to Proceed to Final Cohorts of EHP-101 Phase 2a Systemic Sclerosis Trial
11. Januar 2023 07:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (“EHP” or the “Company”), a clinical-stage biopharmaceutical company developing a new class of medicines to treat...
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
13. April 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
AB Science réalise une levée de fonds de 12,3 millions d'euros
02. März 2020 02:32 ET
|
AB Science
NE DOIT PAS ETRE DISTRIBUE OU PUBLIE, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS D’AMERIQUE, AU CANADA, EN AUSTRALIE OU AU JAPON COMMUNIQUE DE PRESSE AB SCIENCE REALISE UNE LEVEE DE FONDS DE 12,3...
AB Science announces a new fundraising of EUR 12.3 million
02. März 2020 02:32 ET
|
AB Science
NOT FOR DISTRIBUTION, PUBLICATION, RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN REGULATED INFORMATION FOR IMMEDIATE RELEASE AB SCIENCE ANNOUNCES A NEW...
Endonovo Therapeutics Provides SofPulse® To All NFL Teams
23. Dezember 2019 08:30 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today the delivery of SofPulse® evaluation units to all...